Anna C. Pavlick
Founding Director of the Cutaneous Oncology Program · Weill Cornell Medicine and NewYork-Presbyterian
Credentials: · · · · · · · ·
History
- Present
Cutaneous Oncology Program · Weill Cornell Medicine and NewYork-Presbyterian
Present
UMDNJ
Research
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
New England Journal of Medicine · 2015 · 2,283 citations
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
New England Journal of Medicine · 2012 · 1,763 citations
The Lancet Oncology · 2015 · 1,307 citations
44 papers
42 papers
- IO
39 papers
30 papers
27 papers
- JW
22 papers
20 papers
18 papers
Grants
- 2024
National Cancer Institute · P30
Project lead · $541.7K · New York University School of Medicine
- 2004–2006
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $5.3K · New York University School of Medicine
- 1997–2000
Barriers to Latino Participation in Clinical Trials
National Cancer Institute · R03
Contact PI · $73.2K · New York University School of Medicine
Clinical trials
- 2023–2028
Principal investigator · Recruiting · Phase 2
Weill Medical College of Cornell University
- 2015–2016
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Principal investigator · Terminated · Phase 2
Melissa Burgess, MD
- 2010–2013
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Principal investigator · Completed · Phase 1, Phase 2
Nina Bhardwaj
- 2010
Principal investigator · Withdrawn · Phase 2
National Cancer Institute (NCI)